Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

The importance of medical affairs

By Emily Wigginton

- PMLiVE

Innovative Trials partner with Great Ormond Street Hospital Children’s Charity

The patient recruitment company has chosen their UK charity partner for 2022/2023

Innovative Trials

- PMLiVE

BioNTech and Duality Biologics add third ADC candidate to oncology partnership

The companies announced the original agreement covering two antibody-drug conjugates in April

- PMLiVE

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Around 60% of chronic spontaneous urticaria patients are uncontrolled by H1-antihistamines

EU flag

EMA endorses digital measure as primary endpoint in Duchenne muscular dystrophy trials

The decision qualifies SV95C as an alternative to the widely used six-minute walking test

- PMLiVE

Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

The company will gain the first refusal to one of Poseida’s clinical stage programmes

- PMLiVE

New study shows AI model can identify where patients’ cancers originated

The predictions from OncoNPC could enable doctors to choose targeted cancer treatments

- PMLiVE

Insight to impact: how insights are shaping medical affairs strategies

By Max Noble

- PMLiVE

MSD and Astex announce expansion to oncology drug discovery collaboration

Astex will receive $35m upfront plus milestone payments totalling $500m per programme

- PMLiVE

Merck and Ginkgo Bioworks enter biologic manufacturing collaboration worth up to $490m

The companies partnered last year to improve Merck's active pharmaceutical ingredient manufacturing

- PMLiVE

New NHS treatments increase survival rates for babies with spinal muscular atrophy

Around 70 babies are born with the rare muscle-wasting disease each year in the UK

- PMLiVE

UK government unveils vaccine development hub to strengthen pandemic defences

The centre will support the development of vaccines against new threats

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links